Sang Lee is the founder of ABL Bio. ABL Bio has raised $55M in total funding. Latest round: Series A. Backed by Eli Lilly and Company.
Sang Lee is the CEO of ABL Bio, a company specializing in bispecific antibodies. ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform 'Grabody'. The company recently entered an equity investment agreement with Eli Lilly and Company worth KRW 22 billion, with funds allocated to advance its core technologies and explore collaborative opportunities with Lilly. ABL Bio also has a U.S. subsidiary, Neok Bio, focused on bispecific antibody-drug conjugate (ADC) trials.
Full founder directory · Investor directory · Company funding database · Fundraising library